JP2017537927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537927A5 JP2017537927A5 JP2017529805A JP2017529805A JP2017537927A5 JP 2017537927 A5 JP2017537927 A5 JP 2017537927A5 JP 2017529805 A JP2017529805 A JP 2017529805A JP 2017529805 A JP2017529805 A JP 2017529805A JP 2017537927 A5 JP2017537927 A5 JP 2017537927A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- synergistic
- administered
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 80
- 230000002195 synergetic effect Effects 0.000 claims description 51
- 201000011510 cancer Diseases 0.000 claims description 46
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- 238000002648 combination therapy Methods 0.000 claims description 23
- 230000004614 tumor growth Effects 0.000 claims description 17
- 208000034578 Multiple myelomas Diseases 0.000 claims description 16
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 12
- 229960003301 nivolumab Drugs 0.000 claims description 12
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 11
- 229960004137 elotuzumab Drugs 0.000 claims description 11
- 201000009295 smoldering myeloma Diseases 0.000 claims description 11
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229960002621 pembrolizumab Drugs 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087489P | 2014-12-04 | 2014-12-04 | |
| US62/087,489 | 2014-12-04 | ||
| PCT/US2015/063585 WO2016090070A1 (en) | 2014-12-04 | 2015-12-03 | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537927A JP2017537927A (ja) | 2017-12-21 |
| JP2017537927A5 true JP2017537927A5 (enExample) | 2019-01-17 |
Family
ID=55022696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529805A Withdrawn JP2017537927A (ja) | 2014-12-04 | 2015-12-03 | がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170355768A1 (enExample) |
| EP (1) | EP3227335A1 (enExample) |
| JP (1) | JP2017537927A (enExample) |
| KR (1) | KR20170088984A (enExample) |
| CN (1) | CN107249632A (enExample) |
| AU (1) | AU2015358462A1 (enExample) |
| BR (1) | BR112017011538A2 (enExample) |
| CA (1) | CA2969665A1 (enExample) |
| EA (1) | EA201791049A1 (enExample) |
| IL (1) | IL252535A0 (enExample) |
| MX (1) | MX2017007097A (enExample) |
| SG (1) | SG11201704343SA (enExample) |
| WO (1) | WO2016090070A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106008462A (zh) | 2010-12-17 | 2016-10-12 | 诺华股份有限公司 | 一种alk抑制剂的结晶形式 |
| ES2709654T3 (es) | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| MX2019005089A (es) * | 2016-11-02 | 2019-09-10 | Apexigen Inc | Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso. |
| US20210155691A1 (en) * | 2018-04-16 | 2021-05-27 | Adaerata, Limited Partnership | Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| AU772676B2 (en) | 1998-12-23 | 2004-05-06 | Amgen Fremont Inc. | Human monoclonal antibodies to CTLA-4 |
| ATE254615T1 (de) | 1999-02-22 | 2003-12-15 | Biotechnolog Forschung Gmbh | C-21 modifizierte epothilone |
| MXPA02001877A (es) | 1999-08-23 | 2002-08-20 | Dana Farber Cancer Inst Inc | Pd-1, un receptor para b7-4, y usos del mismo. |
| AU784012B2 (en) | 1999-08-24 | 2006-01-12 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US6958115B2 (en) | 2003-06-24 | 2005-10-25 | The United States Of America As Represented By The Secretary Of The Navy | Low temperature refining and formation of refractory metals |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| AU2007281682B2 (en) | 2006-08-07 | 2013-05-16 | Abbvie Biotherapeutics Inc. | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
| PT2068874E (pt) * | 2006-08-07 | 2015-05-21 | Abbvie Biotherapeutics Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi |
| US20080095768A1 (en) | 2006-08-07 | 2008-04-24 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| JP2012507555A (ja) | 2008-10-31 | 2012-03-29 | アボット バイオセラピューティクス コーポレイション | 稀少疾患の治療における抗ｃｓ１抗体の使用 |
| US20130058921A1 (en) | 2009-10-30 | 2013-03-07 | Frits VAN RHEE | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| EP2493485A1 (en) | 2009-10-30 | 2012-09-05 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
| MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
| SG10201700698WA (en) | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
-
2015
- 2015-12-03 AU AU2015358462A patent/AU2015358462A1/en not_active Abandoned
- 2015-12-03 JP JP2017529805A patent/JP2017537927A/ja not_active Withdrawn
- 2015-12-03 US US15/531,538 patent/US20170355768A1/en not_active Abandoned
- 2015-12-03 EA EA201791049A patent/EA201791049A1/ru unknown
- 2015-12-03 MX MX2017007097A patent/MX2017007097A/es unknown
- 2015-12-03 EP EP15816310.5A patent/EP3227335A1/en not_active Withdrawn
- 2015-12-03 SG SG11201704343SA patent/SG11201704343SA/en unknown
- 2015-12-03 KR KR1020177017909A patent/KR20170088984A/ko not_active Withdrawn
- 2015-12-03 CA CA2969665A patent/CA2969665A1/en not_active Abandoned
- 2015-12-03 WO PCT/US2015/063585 patent/WO2016090070A1/en not_active Ceased
- 2015-12-03 CN CN201580065674.2A patent/CN107249632A/zh active Pending
- 2015-12-03 BR BR112017011538A patent/BR112017011538A2/pt not_active IP Right Cessation
-
2017
- 2017-05-25 IL IL252535A patent/IL252535A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537927A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2016518387A5 (enExample) | ||
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| JP2019526595A5 (enExample) | ||
| MA39070A1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| JP2015532292A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2016530280A5 (enExample) | ||
| JP2009518441A5 (enExample) | ||
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| AR105027A1 (es) | Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos | |
| JP2012193216A5 (enExample) | ||
| RU2016151757A (ru) | Антагонисты pdl-1 и pd-1 для лечения hpv-отрицательных форм рака | |
| JP2018503610A5 (enExample) | ||
| FI3464380T3 (fi) | Gp100-spesifisen tcr-anti-cd3 scfv-fuusioproteiinin annosteluohjelma | |
| MX2020012755A (es) | Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37). | |
| JP2015517511A5 (enExample) | ||
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| JP2018522028A5 (enExample) | ||
| JP2018519300A5 (enExample) |